*In Mantle cell lymphoma, Rituxan-Bendamustine beats R-CHOP
with progression free survival of 69 months vs 31 months and with better toxicity profile
except for skin erythematous lesion often seen with Bendamustine.
Showing posts with label skin erythematous lesions. Show all posts
Showing posts with label skin erythematous lesions. Show all posts
Wednesday, March 6, 2013
Subscribe to:
Posts (Atom)